More than a cancer-causing gene is needed to trigger pancreatic cancer, a study led by Mayo Clinic has found. A second factor creates a "perfect storm" that allows tumors to form, the researchers say. The study, published ...
Sep 10, 2012
0
3
The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become resistant to lenvatinib ...
Sep 13, 2022
0
6
Researchers at Mayo Clinic are studying ways to engineer human-like tissue to bolster the body's ability to heal itself. Scientists in the Regenerative Medicine Biomaterials and Biomolecules Lab have engineered biomaterials ...
Aug 26, 2020
0
3
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each ...
Jun 2, 2011
0
0
(HealthDay)—Semiquantitative immunohistochemical expression of progesterone receptor-positive tumor cells improves prediction of survival within luminal A breast cancers, according to a study published online Dec. 10 in ...
Dec 17, 2012
0
0
Although bones have the ability to regenerate and repair themselves, they are generally unable to do so when the injury is larger than a small break or chip. In a study just published in Inflammation and Regeneration, Japanese ...
Jul 25, 2023
0
8
The risk of dying from breast cancer was not related to high mammographic breast density in breast cancer patients, according to a study published August 20 in the Journal of the National Cancer Institute.
Aug 20, 2012
0
0
Drugs introduced more than a decade ago that target mutations in a protein known as the epidermal growth factor receptor (EGFR) held the promise of personalized treatments for a common form of non-small cell lung cancer. ...
May 20, 2015
0
33
(HealthDay)—Underlying leukemia, even before chemotherapy, may pose a neurocognitive risk to young patients, according to a study published online March 29 in JAMA Oncology.
Apr 6, 2018
0
7
Nearly a third of adults with the most common type of brain cancer develop recurrent, invasive tumors after being treated with a drug called bevacizumab. The molecular underpinnings behind these detrimental effects have now ...
Jul 9, 2012
0
0
